Opinion|Videos|February 17, 2025
Bispecific Antibodies in the Relapsed/Refractory DLBCL Treatment Landscape
A discussion of major challenges in using bispecific antibodies in the relapsed/refractory DLBCL setting, focusing on dosing, safety concerns like CRS, and step-up dosing strategies, along with insights on best practices for community clinics; followed by a review of sequencing bispecific antibodies and CAR T-cell therapies in third-line treatment, informed by recent studies on bispecific/CAR T sequencing
Advertisement
Video content above is prompted by the following:
What are major challenges present when using bispecific antibodies in the RR setting of DLBCL?
- Please discuss challenges associated with dosing as well as safety concerns and discuss how they can be managed.
- Step-up dosing (
Dickinson et al. NEJM 2022 ); CRS (Falchi et al. ASH 2023 )
- Step-up dosing (
- What insights can you offer community clinics with regards to best practices when using and initiating bispecific antibodies?
ALL: Please share your thoughts on sequencing bispecific antibodies in the 3L setting.
- Review bispecific/CAR T sequencing and share your thoughts:
Haydu and Abramson Blood Adv 2024 ;Haynes et al. ASH 2024
Advertisement
Related to this article
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Japan approved Optune Pax plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
Revisit Every OncLive On Air Episode From September 2026
3
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
4
UTRxMYCN M1-14 Nets FDA Dual Designations in Soft Tissue Sarcoma
5